UK Biotech Closes €50M Series A for GPCR Drug Discovery
Oxford-based OMass Therapeutics has extended its Series A round by €33M to fund the spectrometry-assisted development of drugs targeting G protein-coupled receptors…
MORERelated News
Introducing Fierce Biotech’s 2024 Fierce 15 – OMass Therapeutics
August 5, 2024
What makes OMass fierce: You can’t fault OMass for its ambition. The company may still be in preclinical development, but it...
Dame Carol Robinson to receive Lifetime Achievement Award for groundbreaking protein analysis work
June 25, 2024
The European Patent Office (EPO) has announced that Dame Carol Robinson, Professor of Chemistry at the University of Oxford, will receive...
5 Pharmaceutical Companies in the UK to Know
March 11, 2024
OMass uses high-resolution mass spectrometry to study protein assemblies and discover new medicines. Its spectrometry platform, called OdyssION, enables better visualization...
